替吉奥和吉西他滨分别联合顺铂一线治疗EGFR野生型的晚期非小细胞肺癌的临床观察

目的:比较替吉奥联合顺铂方案和吉西他滨联合顺铂方案一线治疗表皮生长因子受体(EGFR)基因野生型的晚期非小细胞肺癌的疗效和安全性。方法:选取2010年7月-2011年12月收治的68例符合入组标准的EGFR基因野生型的晚期非小细胞肺癌患者,将其随机分为2组,观察组采用替吉奥联合顺铂方案进行一线化疗;对照组采用吉西他滨联合顺铂方案进行一线化疗。比较2组患者的近期疗效、无进展生存期和不良反应。结果:替吉奥联合顺铂组(观察组)和吉西他滨联合顺铂组(对照组)的总有效率分别为41.2%和38.2%,差异无统计学意义(P>0.05);中位无进展生存期分别为5.4个月和5.1个月,差异无统计学意义(P=0.088);不良反应中替吉奥组的血小板降低发生率(11.8%)低于吉西他滨组,差异有统计学意义(P<0.05)。结论:替吉奥联合顺铂方案一线治疗EGFR基因野生型的晚期非小细胞肺癌具有较好疗效,且不良反应较轻。

Clinical observation of tegafur/gimeracil/oteracil potassium plus cisplatin versus gemcitabine plus cisplatin as the first-line therapies against advanced NSCLC with wild-type EGFR

OBJECTIVE To evaluate efficacy and toxicity of tegafur/gimeracil/oteracil potassium plus cisplatin and gemcitabine plus cisplatin as first-line therapies against advanced NSCLC with wild-type EGFR.METHODS Sixty eight patients of advanced NSCLC with wild-type EGFR were enrolled and randomly divided into tegafur/gimeracil/oteracil potassium plus cisplatin group or gemcitabine plus cisplatin group.Efficacy,progression-free survival(PFS)and toxicity of both groups were compared.RESULTS Objective response rates of tegafur/gimeracil/oteracil potassium plus cisplatin group and gemcitabine plus cisplatin group were 41.2% and 38.2%,respectively.Median progression-free survivals(PFS)in tegafur/gimeracil/oteracil potassium plus cisplatin group and gemcitabine plus cisplatin group were 5.4 and 5.1 months,respectively(P=0.088).For the adverse reactions,there were less thrombocytopenia(11.8%) in tegafur/gimeracil/oteracil potassium plus cisplatin group(P<0.05).CONCLUSION Tegafur/gimeracil/oteracil potassium plus cisplatin is an effective and well-tolerated regimen as first-line therapy against advanced NSCLC with wild-type EGFR.